Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Janssen's Rybrevant, Guardant360 CDx for EGFR Exon 20-Mutated NSCLC

NEW YORK – The US Food and Drug Administration on Friday granted accelerated approval to Janssen Pharmaceutical's EGFR-MET bispecific antibody amivantamab (Rybrevant) as a treatment for EGFR exon 20-mutated non-small cell lung cancer, or NSCLC.

The agency also announced it has approved Guardant Health's Guardant360 CDx, a blood-based next-generation sequencing test designed to detect alterations in 55 genes, as a companion diagnostic to identify patients eligible for amivantamab.

The agency based its decision to approve amivantamab on the results of the Phase I CHRYSALIS trial, in which 81 NSCLC patients harboring EGFR exon 20 insertion mutations, all of whom had disease progression after platinum-based chemotherapy, received amivantamab. The overall response rate among patients treated with amivantamab was 40 percent and the median duration of response was 11.1 months. Sixty-three percent of patients responded to the treatment for more than six months.

Patients with EGFR exon 20 mutations — who comprise around 2 or 3 percent of NSCLCs — typically experience poorer outcomes, and the FDA's amivantamab approval marks the first targeted treatment specifically indicated for patients with these mutations.

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.